Radiopharm Theranostics Ltd has released a press release.
RAD 502 can halt tumour progression and prolong survival
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Placement of Entitlement Offer Shortfall
- 2nd Australian site for Nanomab-PDL-1 Phase 1 trial
- Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan
- Completion of Entitlement Offer
- Radiopharm receives $4.85M R&D tax incentive
Later from Radiopharm Theranostics
- RAD secures Share Facility Agreement of up to A$12.5m
- Radiopharm receives $1.9 M advance on FY24 R&D tax incentive
- Pilot Study Validates RAD Terbium-161 Radiotherapeutics
- Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301
- Half Yearly Report and Accounts
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics